Basit öğe kaydını göster

dc.contributor.authorDiPaola, Frank
dc.contributor.authorOral, Elif A.
dc.contributor.authorNeidert, Adam H.
dc.contributor.authorWesterhoff, Maria
dc.contributor.authorTaylor, Simeon
dc.contributor.authorAkinci, Baris
dc.contributor.authorMeral, Rasimcan
dc.contributor.authorRus, Diana
dc.contributor.authorHench, Rita
dc.date.accessioned2021-12-10T09:50:07Z
dc.date.available2021-12-10T09:50:07Z
dc.identifier.citationAkinci B., Meral R., Rus D., Hench R., Neidert A. H. , DiPaola F., Westerhoff M., Taylor S., Oral E. A. , "The complicated clinical course in a case of atypical lipodystrophy after development of neutralizing antibody to metreleptin: treatment with setmelanotide", ENDOCRINOLOGY DIABETES AND METABOLISM CASE REPORTS, 2020
dc.identifier.othervv_1032021
dc.identifier.otherav_15afd136-e238-4a7b-b142-67ae4253f37e
dc.identifier.urihttp://hdl.handle.net/20.500.12627/168588
dc.identifier.urihttps://avesis.istanbul.edu.tr/api/publication/15afd136-e238-4a7b-b142-67ae4253f37e/file
dc.identifier.urihttps://doi.org/10.1530/edm-19-0139
dc.description.abstractA patient with atypical partial lipodystrophy who had a transient initial response to metreleptin experienced acute worsening of her metabolic state when neutralizing antibodies against metreleptin appeared. Because her metabolic status continued to deteriorate, a therapeutic trial with melanocortin-4 receptor agonist setmelanotide, that is believed to function downstream from leptin receptor in the leptin signaling system, was undertaken in an effort to improve her metabolic status for the first time in a patient with lipodystrophy. To achieve this, a compassionate use (investigational new drug application; IND) was initiated (NCT03262610). Glucose control, body fat by dual-energy X-ray absorptiometry and MRI, and liver fat by proton density fat fraction were monitored. Daily hunger scores were assessed by patient filled questionnaires. Although there was a slight decrease in hunger scales and visceral fat, stimulating melanocortin-4 receptor by setmelanotide did not result in any other metabolic benefit such as improvement of hypertriglyceridemia or diabetes control as desired. Targeting melanocortin-4 receptor to regulate energy metabolism in this setting was not sufficient to obtain a significant metabolic benefit. However, complex features of our case make it difficult to generalize these observations to all cases of lipodystrophy. It is still possible that melanocortin-4 receptor agonistic action may offer some therapeutic benefits in leptin-deficient patients.
dc.language.isoeng
dc.subjectEndokrinoloji ve Metabolizma Hastalıkları
dc.subjectEndocrinology
dc.subjectEndocrine and Autonomic Systems
dc.subjectEndocrinology, Diabetes and Metabolism
dc.subjectLife Sciences
dc.subjectHealth Sciences
dc.subjectDahili Tıp Bilimleri
dc.subjectİç Hastalıkları
dc.subjectSağlık Bilimleri
dc.subjectTıp
dc.subjectKlinik Tıp (MED)
dc.subjectKlinik Tıp
dc.subjectENDOKRİNOLOJİ VE METABOLİZMA
dc.titleThe complicated clinical course in a case of atypical lipodystrophy after development of neutralizing antibody to metreleptin: treatment with setmelanotide
dc.typeMakale
dc.relation.journalENDOCRINOLOGY DIABETES AND METABOLISM CASE REPORTS
dc.contributor.departmentUniversity of Michigan System , ,
dc.contributor.firstauthorID2633768


Bu öğenin dosyaları:

DosyalarBoyutBiçimGöster

Bu öğe ile ilişkili dosya yok.

Bu öğe aşağıdaki koleksiyon(lar)da görünmektedir.

Basit öğe kaydını göster